U.S. Patent and Trademark Office Issues Notice of Allowance of Patent Licensed to Symberix

March 2016

Symberix and licensor, University of North Carolina at Chapel Hill, received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical patent application related to using non-antibiotic, small molecules to address side effects from chemotherapeutic drugs. The patent application is titled “Selective Beta-Glucuronidase Inhibitors as a Treatment for Side Effects of Camptothecin Antineoplastic Agents".